|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| Financial Markets Research: Renovis, Inc.'s NXY-059 - Safety profile and unmet need could drive approval |
|
|
|
|
€ 3 040,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Août 2006 |
Taille du document : |
14 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (2) |
|
|
|
| 109 pages | Février 2003 | Anglais
|
|
|
| Main
focus: |
roof,wall,roofing,heating systems,heating system,...
|
| Research
focus: |
industry structure,market definition, |
| Geographic
focus: |
united kingdom,sweden |
| |
|
|
|
|
| 150 pages | Février 2007 | Anglais
|
|
|
| Main
focus: |
liquor,theme park,entertainment
|
| Research
focus: |
market outlook,demand analysis,advertising, |
| Geographic
focus: |
poland |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Pharmaceutical Mergers & Aquisitions: the third wave
160 pages | Février 1999 |
Historical assessment : The report identifies the factors that have driven the two historical waves of M&A activity, and analyses the relative importance of these factors through case studies.
795,00 €
|
|
| |
| |
Lifestyle Drugs Outlook to 2005
130 pages | Février 1999 |
Definition of lifestyle drugs : The disease, product and social characteristics that make a drug lifestyle drug.
Epidemiology : The patient potential for lifestyle drugs such as sexual dysfuncti |
795,00 €
|
| |
| |
The Generics Outlook 2001
242 pages | Février 2001 |
“By the year 2004, it is expected that the value of the total western European generics sector may have risen to $19 billion, representing almost 15% of allpharmaceuticals.
In the USA, the val |
955,00 €
|
| |
| |
The Diagnostics Outlook to 2005
130 pages | Février 1999 |
Diagnostic market : The current in vitro diagnostic (IVD) market is discussed, identifying how the market can be segmented according to country, end user, clinical speciality and disease area.
795,00 €
|
|
| |
| |
Chinese Markets for Pharmaceuticals
225 pages | Janvier 2002 |
China's demand for pharmaceuticals has grown at a fast pace in the past decade.
In the next five years, both production and demand will continue to grow.
This new study examines China's economic |
3 500,00 €
|
| |
| |
The Pharmaceutical Profitability Outlook
150 pages | Février 1999 |
Is pharmaceutical profitability sustainable into the 21st century? “As the pharmaceutical industry finds itself at a crossroads, the strategic directions companies take will be pivotal in determini |
795,00 €
|
| |
| |
Pain Therapeutics: A Strategic Re-evaluation.
198 pages | Août 2000 |
Pain management, though not a life-threatening disease, will have its proper place in the future healthcare system because the disability and economic loss in addition to personal suffering caused |
955,00 €
|
| |
| |
OTC Cough and Cold Remedies in Germany
15 pages | Juillet 2002 |
The German market for OTC cough and cold remedies reached a value of Euro 972 million (US$ 918 million) in 2001, up 0.4% on the previous year.
During the review period, the market grew by 9.4%, an |
198,00 €
|
| |
| |
The CNS Outlook 2000
203 pages | Octobre 2000 |
The Central Nervous System (CNS) market has shown sustained growth in 1999 with the expansion continuing to be driven by several factors.A greater understanding of the neuropharmacological mechanisms |
955,00 €
|
| |
| |
Patient Power in the Pharmaceutical Industry: The shift towards more informed, more powerful consumers of drugs
119 pages | Juin 1999 |
The dramatic rise in patient power in recent years presents a new and challenging opportunity to pharmaceutical companies, healthcare providers and governments alike.
A great need exists for ph |
795,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Financial Markets Research: Renovis, Inc.'s NXY-059 - Safety profile and unmet need could drive approval |
|
|
Introduction
Renovis and AstraZeneca's NXY-059 is viewed as the most promising neuroprotectant currently in development for stroke, however, much of its potential is dependent upon its ability to demonstrate a benefit in the recently enrolled SAINT-II trial.
Scope
Analyzes the regulatory and commercial potential for RNVS' NXY-059, a novel agent that aims to reduce brain damage post-ischemic stroke
Datamonitor interviewed four neurologists familiar with NXY-059 and its clinical data regarding its potential for the treatment of ischemic stroke
Highlights
Pending results from the Phase III SAINT-II trial expected later this year, we estimate that NXY-059's safety profile and the modifications to the Phase III trial could support its eventual approval in early 2008, leading to blockbuster potential by 2012.
If approved in early 2008, we expect that Renovis and AstraZeneca's NXY-059 would be rapidly utilized in eligible patients due to its strong safety profile and lack of alternative options.
As a result, we forecast worldwide NXY-059 revenues that fall only slightly below long-term Wall Street consensus.
Reasons to Purchase
Understand the regulatory and commercial potential for Renovis' NXY-059 through in-depth analysis, based on interviews with leading experts
Anticipate likely changes in the future market dynamics for stroke therapies if approval of NXY-059 occurs
|
|
Introduction
Renovis and AstraZeneca's NXY-059 is viewed as the most promising neuroprotectant currently in development for stroke, however, much of its potential is dependent upon its ability to demonstrate a benefit in the recently enrolled SAINT-II trial.
Scope
Analyzes the regulatory and commercial potential for RNVS' NXY-059, a novel agent that aims to reduce brain damage post-ischemic stroke
Datamonitor interviewed four neurologists familiar with NXY-059 and its clinical data regarding its potential for the treatment of ischemic stroke
Highlights
Pending results from the Phase III SAINT-II trial expected later this year, we estimate that NXY-059's safety profile and the modifications to the Phase III trial could support its eventual approval in early 2008, leading to blockbuster potential by 2012.
If approved in early 2008, we expect that Renovis and AstraZeneca's NXY-059 would be rapidly utilized in eligible patients due to its strong safety profile and lack of alternative options.
As a result, we forecast worldwide NXY-059 revenues that fall only slightly below long-term Wall Street consensus.
Reasons to Purchase
Understand the regulatory and commercial potential for Renovis' NXY-059 through in-depth analysis, based on interviews with leading experts
Anticipate likely changes in the future market dynamics for stroke therapies if approval of NXY-059 occurs
|
|
|
PPLSEN
|
|
|
|
|
